🔗 Share this article

As America proceeds with unprecedented adjustments to its immunization schedules, a particular individual has emerged in a surprising turn: Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines throughout the global health crisis and has focused upon potential deaths after COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Public health authorities planned to unveil radical revisions to the childhood immunization program recently, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US out of alignment with much of the international standard with no evidence for benefit. This reveal has been postponed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to present at the event. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to run the office this calendar year.

Consolidating Power at the Agency

This interim role could signify a closer partnership between the drug and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending some pediatric immunization guidelines in the US to become more similar to the Danish model, a society with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial statements, she has kept her attention on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Expertise

Høeg has no apparent track record in pharmaceutical research, approval processes or leadership, which has been standard for former heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in leading a major agency. She lacks background in drug approvals.”

Former heads of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that previous people who headed CBER have had.”

The drug center has an enormous workload at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and each of these must be supervised,” Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative component to the role, which manages in excess of 5,000 staff members. “It’s a huge leadership role, if you perform it correctly,” the former official added.

Response and Disputed Policies

When asked about concerns about Dr. Høeg's qualifications and whether this selection represents increased cooperation among agency officials on vaccines, a press secretary stated that the “concerns stem from flawed premises”.

“Her resume is consistent with the functions of her position,” the official explained, citing the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious rapid medication authorization process that reportedly concerned her predecessors. “By what process are these drugs being chosen for this voucher program? Who makes the choices?” Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards laxer rules of most medications, aside from vaccines.”

Documented Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, past, critics said. She released a research paper using non-validated volunteer-provided data to determine the rate of heart inflammation after Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the new government encompassed altering guidelines for recently developed shots and ending “non-essential” immunizations, she stated post-election on a audio program. At the FDA, Dr. Høeg has allegedly suggested preventing teenage boys from obtaining COVID-19 vaccines.

“She is an thorough ideologue who commences with her conclusions and tailors the evidence to retrofit the evidence in a highly deceptive, untruthful way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|